With strong results for ZX008, Zogenix set to become a key player in epilepsy
USA-based CNS-focused biotech Zogenix’ (Nasdaq: ZGNX) positive results for its drug ZX008 (fenfluramine hydrochloride) and the subsequent approval that is likely to follow, will push Zogenix to become a key player in the epilepsy market.
Zogenix’ drug will treat young children and adolescents suffering from Dravet syndrome. The results will allow Zogenix to push ahead with its plan to submit regulatory filings in the US and European Union markets in fourth-quarter 2018, swiftly following GW Pharmaceutical’s (Nasdaq: GWPH) Epidiolex (cannabidiol), according to analytics company GlobalData.
GlobalData’s report: ‘ PharmaPoint: Epilepsy – Global Drug Forecast and Analysis to 2026,’ highlights that Dravet syndrome is a rare form of pediatric epilepsy that has proved difficult to treat, with current therapies showing poor efficacy, safety, or tolerability profiles. As such, treatments for this form of epilepsy are one of the more significant needs in the epilepsy market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze